Supplementary tables.docx (58.66 kB)

Supplementary tables: Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.docx

dataset

posted on 2021-08-31, 10:31 authored by Kendra DeBusk, Shaun Abeysinghe, Adrian Vickers, Anubhav Nangia, Judith Bell, Chiemeka Ike, Andres Forero-Torres, Matthew T Blahna

Supplementary Table 1. Search terms used in Embase (A) Initial systematic review search, January 22, 2020; (B, C) November 23, 2020

Supplementary Table 2. Systematic literature review eligibility criteria used to identify relevant randomized trials

Supplementary Table 3. Risk of bias assessment for studies included in the NMA

Funding

Seattle Genetics

History

Usage metrics

Read the peer-reviewed publication

Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis

Future Oncology

Keywords

Human epidermal growth factor receptor 2 metastatic breast cancer network meta-analysis overall survival progression-free survival second-line third-line Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0